Narrow search
Showing 1 - 10 of 113
Cover Image
Estimating cost-effectiveness in public health : a summary of modelling and valuation methods
Marsh, Kevin; Phillips, Ceri; Fordham, Richard; … - In: Health economics review 2 (2012) 17, pp. 1-6
that two key developments are required if this vision is to be achieved. First, there is a trend to modelling approaches … consider a broader range of modelling techniques than are currently employed to assess public health interventions. The … selection and implementation of alternative modelling techniques should be facilitated by the production of better data on the …
Persistent link: https://www.econbiz.de/10009753411
Cover Image
Micro-costing in health and medicine : a critical appraisal
Xu, Xiao; Lazar, Christina M.; Ruger, Jennifer Prah - In: Health economics review 11 (2021) 1/1, pp. 1-8
Background: Concerns about rising health care costs require rigorous economic study to inform clinical and policy decision-making. Micro-costing is a cost estimation methodology employing detailed resource utilization and unit cost data to generate precise estimates of economic costs....
Persistent link: https://www.econbiz.de/10012482926
Cover Image
How much does community-based targeting of the ultra-poor in the health sector cost? : novel evidence from Burkina Faso
Beaugé, Yvonne; Koulidiati, Jean-Louis; Ridde, Valéry; … - In: Health economics review 8 (2018) 19, pp. 1-11
Background: Targeting efforts aimed at increasing access to care for the poorest by reducing to a minimum or completely eliminating payments at point of use are increasingly being adopted across low and middle income countries, within the framework of Universal Health Coverage policies. No...
Persistent link: https://www.econbiz.de/10011896552
Cover Image
Harmonization issues in unit costing of service use for multi-country, multi-sectoral health economic evaluations : a scoping review
Fischer, Claudia; Mayer, Susanne; Perić, Nataša; … - In: Health economics review 12 (2022) 1, pp. 1-13
Background: Valuation is a critical part of the costing process in health economic evaluations. However, an overview of specific issues relevant to the European context on harmonizing methodological requirements for the valuation of costs to be used in health economic evaluation is lacking. We...
Persistent link: https://www.econbiz.de/10013329785
Cover Image
Evaluating the administration costs of biologic drugs : development of a cost algorithm
Tetteh, Ebenezer K.; Morris, Stephen - In: Health economics review 4 (2014) 26, pp. 1-16
Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses or health technology assessments to...
Persistent link: https://www.econbiz.de/10010526930
Cover Image
Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain
Blasco, Antonio J.; Lázaro, Pablo; Caballero, Teresa; … - In: Health economics review 3 (2013) 2, pp. 1-11
Background: Icatibant is the only subcutaneous treatment for acute Type I and Type II hereditary angioedema with C1-esterase inhibitor deficiency (HAE-C1-INH) licensed for self-administration in Europe. Aim: To compare the economic impact of two icatibant administration strategies: health...
Persistent link: https://www.econbiz.de/10009755347
Cover Image
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
Sanchez-de la Rosa, Rainel; Sabater, Eliazar; Casado, … - In: Health economics review 3 (2013) 13, pp. 1-5
Background: Fingolimod is an innovative drug with a significant budget impact in the treatment of MS in Spain. The aim of this study was to calculate the direct cost comparison of glatiramer acetate and fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS)...
Persistent link: https://www.econbiz.de/10009755990
Cover Image
Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?
Knoll, Stefanie; Mair, Christoph; Benter, Ursula; Vouk, … - In: Health economics review 3 (2013) 27, pp. 1-11
Background: Rotavirus gastroenteritis (RVGE) is a frequent disease in young children. The recommended German paediatric immunisation schedule does not currently include rotavirus vaccination. A lack of economic data on the impact of routine vaccination is stated as one of the reasons. As a...
Persistent link: https://www.econbiz.de/10010242226
Cover Image
Simulation model for cost estimation of integrated care concepts of heart failure patients
Schroettner, Joerg; Lassnig, Alexander - In: Health economics review 3 (2013) 26, pp. 1-11
: For modelling, the discrete event technique was used. The model takes outpatient care as well as inpatient care into …
Persistent link: https://www.econbiz.de/10010242232
Cover Image
Do health economic evaluations using observational data provide reliable assessment of treatment effects?
Rovithis, Dimitrios - In: Health economics review 3 (2013) 21, pp. 1-7
Economic evaluation in modern health care systems is seen as a transparent scientific framework that can be used to advance progress towards improvements in population health at the best possible value. Despite the perceived superiority that trial-based studies have in terms of internal...
Persistent link: https://www.econbiz.de/10010242258